Esperion Therapeutics (ESPR) Misses Q3 EPS by 18c
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.16), $0.18 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $87.3 million versus the consensus estimate of $92.5 million.
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- Boeing wins $121 million Navy contract for P-8A upgrades
- Lockheed Martin wins $83 million Army missile contract
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
